Numerous studies have shown that ERK5 inhibitors have antitumor activity by activating apoptosis in cancer cells and in tumor xenografts (reviewed in Gomez et al. (2016), Hoang et al. (2017), Stecca and Rovida (2019)). This evidence concerns the gene MAPK7 and cancer.